Guangdong Biolight Meditech Co Ltd (300246) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guangdong Biolight Meditech Co Ltd (300246) has a cash flow conversion efficiency ratio of 0.049x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥62.62 Million ≈ $9.16 Million USD) by net assets (CN¥1.29 Billion ≈ $188.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guangdong Biolight Meditech Co Ltd - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Guangdong Biolight Meditech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Guangdong Biolight Meditech Co Ltd (300246) financial obligations for a breakdown of total debt and financial obligations.
Guangdong Biolight Meditech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guangdong Biolight Meditech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Charter Hall Social Infrastructure REIT
AU:CQE
|
0.015x |
|
Placoplatre SA
PA:MLPLC
|
N/A |
|
Spearhead Integrated Marketing
SHE:300071
|
-0.019x |
|
Yuanta Sec Kor
KO:003470
|
-0.033x |
|
Troax Group AB
ST:TROAX
|
0.027x |
|
Jiangsu Kuangshun Photosensitivity New-Material Stock Co Ltd
SHE:300537
|
0.020x |
|
Thai Vegetable Oil Public Company Limited
BK:TVO
|
-0.048x |
|
PetroVietnam Fertilizer and Chemicals Corp
VN:DPM
|
-0.106x |
Annual Cash Flow Conversion Efficiency for Guangdong Biolight Meditech Co Ltd (2008–2024)
The table below shows the annual cash flow conversion efficiency of Guangdong Biolight Meditech Co Ltd from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see 300246 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.29 Billion ≈ $188.93 Million |
CN¥-8.64 Million ≈ $-1.26 Million |
-0.007x | -107.20% |
| 2023-12-31 | CN¥1.39 Billion ≈ $203.25 Million |
CN¥129.05 Million ≈ $18.88 Million |
0.093x | -0.80% |
| 2022-12-31 | CN¥1.50 Billion ≈ $219.85 Million |
CN¥140.72 Million ≈ $20.59 Million |
0.094x | +15.30% |
| 2021-12-31 | CN¥992.38 Million ≈ $145.22 Million |
CN¥80.61 Million ≈ $11.80 Million |
0.081x | -81.59% |
| 2020-12-31 | CN¥1.03 Billion ≈ $151.14 Million |
CN¥455.78 Million ≈ $66.70 Million |
0.441x | +217.50% |
| 2019-12-31 | CN¥585.84 Million ≈ $85.73 Million |
CN¥81.43 Million ≈ $11.92 Million |
0.139x | +6.49% |
| 2018-12-31 | CN¥622.19 Million ≈ $91.05 Million |
CN¥81.21 Million ≈ $11.88 Million |
0.131x | +0.02% |
| 2017-12-31 | CN¥554.08 Million ≈ $81.08 Million |
CN¥72.31 Million ≈ $10.58 Million |
0.130x | +29.53% |
| 2016-12-31 | CN¥504.27 Million ≈ $73.79 Million |
CN¥50.81 Million ≈ $7.43 Million |
0.101x | +63.51% |
| 2015-12-31 | CN¥460.87 Million ≈ $67.44 Million |
CN¥28.40 Million ≈ $4.16 Million |
0.062x | -37.68% |
| 2014-12-31 | CN¥427.94 Million ≈ $62.62 Million |
CN¥42.31 Million ≈ $6.19 Million |
0.099x | +42.54% |
| 2013-12-31 | CN¥393.88 Million ≈ $57.64 Million |
CN¥27.32 Million ≈ $4.00 Million |
0.069x | -35.30% |
| 2012-12-31 | CN¥377.93 Million ≈ $55.30 Million |
CN¥40.52 Million ≈ $5.93 Million |
0.107x | +30.72% |
| 2011-12-31 | CN¥354.32 Million ≈ $51.85 Million |
CN¥29.06 Million ≈ $4.25 Million |
0.082x | -81.60% |
| 2010-12-31 | CN¥89.93 Million ≈ $13.16 Million |
CN¥40.09 Million ≈ $5.87 Million |
0.446x | +73.55% |
| 2009-12-31 | CN¥66.94 Million ≈ $9.80 Million |
CN¥17.19 Million ≈ $2.52 Million |
0.257x | -5.70% |
| 2008-12-31 | CN¥46.53 Million ≈ $6.81 Million |
CN¥12.68 Million ≈ $1.85 Million |
0.272x | -- |
About Guangdong Biolight Meditech Co Ltd
Guangdong Biolight Meditech Co., Ltd. engages in the research and development, production, sale, and service of medical devices products and solutions in China. It operates in two segments, Life Information and Support, and Kidney Disease. The company offers emergency and critical care monitor, subcritical care monitor, general ward monitor, outpatient monitor, neonatal monitor, infusion pump, el… Read more